Verrica Pharmaceuticals Inc.（VRCA）宣布其关于VP-315治疗基底细胞癌潜在远端效应的晚期突破性摘要，已获选将在2026年皮肤病研究学会（SID）年会上进行展示。这一突破性研究揭示了VP-315在局部治疗中可能引发的系统性免疫反应，为基底细胞癌的治疗提供了新的视角。该摘要的接受不仅彰显了Verrica制药在皮肤科创新疗法领域的领先地位，也预示着VP-315有望成为首个展现远端效应的局部治疗药物。研究人员指出，若临床效果得到进一步验证，这种新型免疫机制或将为多种实体瘤治疗开辟全新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.